Vitamins and stroke: The homocysteine hypothesis still in doubt

Neurologist

Volumn 14, Issue 1, 2008, Pages 2-4

  Ntaios, George C ^a   Savopoulos, Christos G ^a   Chatzinikolaou, Anastasia C ^a   Kaiafa, Georgia D ^a   Hatzitolios, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cardiovascular risk; cIMT; Folate; Homocysteine

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ARTERIAL WALL THICKENING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; FOLIC ACID; HOMOCYSTEINE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; STROKE; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B 6;

EID: 38349039656     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000253066.85963.aa     Document Type: Review

References (24)

1. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
2. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
3. Al-Obaidi MK, Stubbs PJ, Collinson P, et al. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol. 2000;36:1217-1222.
4. Matetzky S, Freimark D, Ben-Ami S, et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med. 2003;163:1933-1937.
5. Tanne D, Haim M, Goldbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke. 2003;34:632-636. Epub 2003 Feb 20.
6. Schnyder G, Flammer Y, Roffi M, et al. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol. 2002;40:1769-1776.
7. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
8. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
9. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
10. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111.
11. McQuillan BM, Beilby JP, Nidorf M, et al. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening: the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation. 1999;99:2383-2388.
12. Rasouli ML, Nasir K, Blumenthal RS, et al. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005;181:159-165.
13. Ubbink JR, Vermaak WJ, van der Merwe A, et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47.
14. Neal B, MacMahon S, Ohkubo T, et al. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. Eur Heart J. 2002;23:1509.
15. MRC Vitamin Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137.
16. US Food and Drug Administration. Food labeling: health claims and label statements: folate and neural tube defects. Fed Reg. 1993;58:532-545.
17. Grosse SD, Waitzman NJ, Romano PS, et al. Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. Am J Public Health. 2005;95:1917-1922.
18. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355:517-522.
19. Till U, Röhl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis. 2005;181:131-135.
20. Marcucci R, Zanazzi M, Bertoni E, et al. Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplant Proc. 2005;37:2491-2492.
21. Toole JF, Malinow R, Chambless L, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the Vitamin Intervention for Stroke Prevention (VISP) Randomised Controlled Trial. JAMA. 2004;291:565-575.
22. Bostom AG, Selhub J, Jacques PF, et al. Power shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med. 2001;135:133-137.
23. β-Vitamin Treatment Triallist's Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151:282-287.
24. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99:178-182.